NeoImmuneTech네오이뮨텍
950220 · KOSDAQ · ₩950220 · 네오이뮨텍
Valuation model · Discounted cash flow (DCF)
We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.
Fair value per share
With these assumptions the model gives no positive value.
- Enterprise value
- −₩82M
- Equity value
- −₩66M
- WACC
- 7.3%
Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.
Why the model and the price differ
The model gives no positive value at these assumptions. What we can see:
- No operating margin up to 90% gets the model to today's price at these growth assumptions.
- In the projection, spending on equipment, software and working capital takes most or all of the after-tax operating profit, so free cash flow is thin. Companies that invest heavily often look like this until spending slows.
Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.
Bear / Base / Bull
- Bear
- —
- Base
- —
- Bull
- —
Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.
Assumptions
Sign in to change the assumptions and see the results update. Sign in
Cycle options
Margin path
Every year uses the cycle-average margin (−20.0%).
Revenue growth
- -10%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (-46.6% a year, annual reports), fading to 3% by year 5.
- -6.7%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (-46.6% a year, annual reports), fading to 3% by year 5.
- -3.5%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (-46.6% a year, annual reports), fading to 3% by year 5.
- -0.2%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (-46.6% a year, annual reports), fading to 3% by year 5.
- 3%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (-46.6% a year, annual reports), fading to 3% by year 5.
Business
- -20%
Operating profit as a share of revenue.
Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.
- 27.5%
Share of operating profit paid as corporate tax.
Default: Korea's top corporate tax rate (25%) plus 10% local income tax.
- 3,397.1%
The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).
Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).
- 4,246.3%
Money spent on factories, equipment, software and other long-term assets (% of revenue).
Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).
- -10%
Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.
Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.
Discount rate
- 2%
How fast cash flows keep growing every year after year 5.
Default: about Korea's long-run inflation plus real growth.
- 4.01%
Yield on Korea's 10-year government bond: the return with almost no risk.
Default: Korea Treasury Bond 10-year yield on 2026-10-30.
- 0.6
How much the share moves when the market moves: 1 means just like the market.
Default: 105 weeks of weekly returns against KOSPI (official index); raw beta -0.22, adjusted toward 1 and kept between 0.6 and 2.0.
- 5.5%
The extra return investors want for owning shares instead of bonds.
Default: a typical premium for Korean shares.
- 5.51%
The interest rate the company would pay to borrow.
Default: the 10-year yield plus a 1.5% credit spread.
Starting point
- Revenue (TTM to H1 2026)
- ₩1.2M
- Net debt (borrowings and leases − cash and deposits)
- −₩16M
- Shares
- 34,211,840
- Share price
- ₩1,576
- Market cap
- ₩54B
TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.
Past years and projection
Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.
| FY2023 | FY2024 | FY2025 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₩0 | ₩124,917 | ₩66,673 | ₩1.1M | ₩997,442 | ₩962,531 | ₩960,606 | ₩989,425 |
| Growth | — | — | −46.6% | −10.0% | −6.7% | −3.5% | −0.2% | 3.0% |
| EBIT | −₩43M | −₩29M | −₩18M | −₩213,814 | −₩199,488 | −₩192,506 | −₩192,121 | −₩197,885 |
| EBIT margin | — | −23,497.6% | −26,596.6% | −20.0% | −20.0% | −20.0% | −20.0% | −20.0% |
| After-tax EBIT | −₩31M | −₩21M | −₩13M | −₩155,015 | −₩144,629 | −₩139,567 | −₩139,288 | −₩143,467 |
| + Depreciation | — | — | — | ₩36M | ₩34M | ₩33M | ₩33M | ₩34M |
| − Capital spending | ₩613,764 | ₩1.1M | ₩5.1M | ₩45M | ₩42M | ₩41M | ₩41M | ₩42M |
| − Working capital | ₩289,057 | −₩9.3M | ₩5.6M | ₩11,879 | ₩7,163 | ₩3,491 | ₩193 | −₩2,882 |
| Free cash flow | — | — | — | −₩9.2M | −₩8.6M | −₩8.3M | −₩8.3M | −₩8.5M |
| Discount factor | — | — | — | 0.932 | 0.868 | 0.809 | 0.754 | 0.703 |
| Present value | — | — | — | −₩8.6M | −₩7.5M | −₩6.7M | −₩6.3M | −₩6M |
Terminal value −₩67M, worth −₩47M today: 57% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.
Cross-check: what the market has paid before
For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:
| Low | Typical | High | |
|---|---|---|---|
| Price / book (book value ₩1 a share)Now 1474.2× | ₩2,3182168.0× | ₩5,2934951.1× | ₩8,3617820.9× |
Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.
Sensitivity
Fair value per share as two inputs change; the middle is the current case.
| WACC ↓ · Terminal growth → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 6.3% | — | — | — | — | — |
| 6.8% | — | — | — | — | — |
| 7.3% | — | — | — | — | — |
| 7.8% | — | — | — | — | — |
| 8.3% | — | — | — | — | — |
Now (TTM)
- Market cap
- ₩54B
- Enterprise value
- ₩54B
- P/E
- —
- P/B
- 1,474.2×
- P/S
- 45,390.9×
- EV/EBITDA
- —
- Dividend yield
- 0.0%
Over time (at each year end)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Price | ₩4,105 | ₩4,835 | ₩8,704 | ₩17,171 | ₩44,485 |
| Market cap | ₩140B | ₩165B | ₩298B | ₩587B | ₩1.5T |
| P/E | — | — | — | — | — |
| P/B | 3,403.3× | 5,836.9× | 5,129.0× | 6,220.0× | 11,134.2× |
| P/S | 2,106,361.8× | 1,324,275.5× | — | — | — |
| EV/EBITDA | — | — | — | — | — |
| Dividend yield | 0.0% | — | — | — | — |
Versus similar companies
| Company | P/E | P/B | P/S | EV/EBITDA | Dividend yield |
|---|---|---|---|---|---|
| NeoImmuneTech | — | 1,474.2× | 45,390.9× | — | 0.0% |
| Samsung Biologics | 34.7× | 8.2× | 15.1× | — | 0.0% |
| Celltrion | 28.2× | 2.5× | 9.1× | — | 0.0% |
| Alteogen | 76.3× | 27.5× | 58.0× | — | 0.1% |
| SK biopharmaceuticals | 15.2× | 6.0× | 7.1× | — | 0.0% |
| Yuhan | 23.3× | 2.3× | 2.4× | 30.4× | 0.8% |
| HLB | — | 15.5× | 54.7× | — | 0.0% |
| Similar companies (median) | 28.2× | 7.1× | 12.1× | 30.4× | 0.0% |
Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.
Also known as: NeoImmuneTech / 네오이뮨텍 / 950220 / KRX:950220
Source: KRX statistical information